NAUT trades 162.1% below Wall Street's consensus target of $2.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NAUT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Nautilus Biotechnolgy, Inc. (NAUT) has a Wall Street consensus price target of $2.50, based on estimates from 5 covering analysts. With the stock currently trading at $0.95, this represents a potential upside of +162.1%. The company has a market capitalization of $121M.
Analyst price targets range from a low of $2.50 to a high of $2.50, representing a 0% spread in expectations. The median target of $2.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NAUT trades at a trailing P/E of -2.0x. Analysts expect EPS to grow -14.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CDNACareDx, Inc | $2.8B | $54.31 | $58.75 | +8.2% | Buy | 45.1x | 13 |
 SEERSeer, Inc. | $99M | $1.80 | $4.00 | +122.2% | Hold | — | 4 |
 QBTSD-Wave Quantum Inc. | $6.2B | $16.81 | $34.38 | +104.5% | Buy | — | 13 |
 ILMNIllumina, Inc. | $38.6B | $255.38 | $210.67 | -17.5% | Buy | 47.7x | 50 |
 PACBPacific Biosciences of California, Inc. | $438M | $1.41 | $1.18 | -16.3% | Buy | — | 18 |
 BFLYButterfly Network, Inc. | $2.4B | $9.20 | $5.19 | -43.6% | Buy | — | 7 |
 TWSTTwist Bioscience Corporation | $9.9B | $158.47 | $116.33 | -26.6% | Buy | — | 14 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.37 | $59.50 | +144.2% | Buy | — | 27 |
 SRPTSarepta Therapeutics, Inc. | $2.0B | $18.95 | $23.33 | +23.1% | Buy | 5.7x | 55 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
Quick answers to the most common questions about buying NAUT stock.
The consensus Wall Street price target for NAUT is $2.5, representing 162.1% upside from the current price of $0.9539. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NAUT has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $2.5 implies 162.1% upside from current levels.
NAUT's current price is $0.9539 with a consensus target of $2.5 (162.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $2.5 for NAUT, while the most conservative target is $2.5. The consensus of $2.5 represents the median expectation. These targets typically reflect 12-month expectations.
NAUT is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NAUT stock forecast based on 5 Wall Street analysts shows a consensus price target of $2.5, with estimates ranging from $2.5 (bear case) to $2.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NAUT, with a "Buy" consensus rating and $2.5 price target (162.1% upside). 3 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NAUT analyst price targets range from $2.5 to $2.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.